Gras Emmanuelle, Bergeron Emmanuelle, Puges Mathilde, Ducours Maïlys, Leleux Charlotte, Amoureux Lucie, Jean Baptiste, Bendjelloul Imane, Camelena François, Chenouard Rachel, Mahieu Rafael, Lemenand Olivier, Toro Alexandre, Lecoustumier Alain, Lortholary Olivier, Rodriguez Nava Véronica, Lebeaux David
Université Paris Cité, Paris, France.
Department of Microbiology, Antimicrobial Stewardship Team, European Hospital Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France.
Open Forum Infect Dis. 2022 Jun 6;9(7):ofac271. doi: 10.1093/ofid/ofac271. eCollection 2022 Jul.
are environmental gram-positive bacilli that can cause ubiquitous mycetoma and, more rarely, invasive infections. We describe the clinical relevance of spp. identified in human samples and characteristics of patients with invasive infections.
We conducted a retrospective (2006-2017) study of isolates identified in clinical samples in French microbiology laboratories. genus was confirmed by a specific 16S rRNA polymerase chain reaction, and antibiotic susceptibility testing was performed by disk diffusion and trimethoprim-sulfamethoxazole minimum inhibitory concentration (E-test) if resistance was suspected. Patient characteristics, treatments, and outcomes were collected. Invasive infection was defined as a positive culture from a sterile site with signs of infection but without cutaneous inoculation.
Of 137 isolates, all were susceptible to amikacin (113/113) and linezolid (112/112), and 92.9% to imipenem (105/113). Using disk diffusion, 50.9% (57/112) of isolates were susceptible to trimethoprim-sulfamethoxazole, but most of the apparently resistant isolates (25/36, 69.4%) tested by E-test were ultimately classified as susceptible. Clinical data were obtained for 63/137 (45.9%) isolates: 30 (47.6%) invasive infections, 8 (12.7%) primary cutaneous infections, 22 (34.9%) contaminations, 3 (4.7%) respiratory colonization. Patients with invasive infection were more frequently receiving corticosteroids than patients without invasive infection (11/30, 36.7%, vs 2/25, 8.0%; = .03), and at 6-month follow-up, 14 of them were cured, 3 had relapsed, 4 were dead, and 9 were lost to follow-up.
Half of the clinical samples that grew were from patients with invasive infection. In that case, antimicrobial therapy should include 1 or 2 antibiotics among linezolid, amikacin, or imipenem.
是环境革兰氏阳性杆菌,可引起普遍存在的足菌肿,较少引起侵袭性感染。我们描述了在人类样本中鉴定出的菌种的临床相关性以及侵袭性感染患者的特征。
我们对法国微生物实验室临床样本中鉴定出的分离株进行了一项回顾性研究(2006 - 2017年)。通过特异性16S rRNA聚合酶链反应确认菌种,如果怀疑有耐药性,则通过纸片扩散法和甲氧苄啶 - 磺胺甲恶唑最低抑菌浓度(E试验)进行药敏试验。收集患者特征、治疗方法和结果。侵袭性感染定义为来自无菌部位的培养阳性且有感染迹象但无皮肤接种。
在137株分离株中,所有菌株对阿米卡星(113/113)和利奈唑胺(112/112)敏感,92.9%对亚胺培南敏感(105/113)。使用纸片扩散法,50.9%(57/112)的分离株对甲氧苄啶 - 磺胺甲恶唑敏感,但通过E试验检测的大多数明显耐药的分离株(25/36,69.4%)最终被归类为敏感。获得了63/137(45.9%)分离株的临床数据:30例(47.6%)侵袭性感染,8例(12.7%)原发性皮肤感染,22例(34.9%)污染,3例(4.7%)呼吸道定植。侵袭性感染患者比无侵袭性感染的患者更频繁地接受皮质类固醇治疗(11/30,36.7%,对比2/25,8.0%;P = 0.03),在6个月的随访中,其中14例治愈,3例复发,4例死亡,9例失访。
培养出的临床样本中有一半来自侵袭性感染患者。在这种情况下,抗菌治疗应包括利奈唑胺、阿米卡星或亚胺培南中的1种或2种抗生素。